Page 108 - 《中国药房》2023年12期

[17] SHI F H，LI H，CUI M，et al. Efficacy and safety of once- Herzegovina，Greece，and Slovenia[J]. Value Health，
weekly semaglutide for the treatment of type 2 diabetes：a 2020，23：S512.
systematic review and meta-analysis of randomized con‐ [27] GORGOJO-MARTÍNEZ J J，MALKIN S J P，MARTÍN
trolled trials[J]. Front Pharmacol，2018，9：576. V，et al. Assessing the cost-effectiveness of a once-weekly
[18] KANTERS S，WILKINSON L，LOPES S，et al. Syste- GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish
matic literature review and indirect treatment comparison setting：once-weekly semaglutide versus empagliflozin[J].
of the efficacy of semaglutide versus empagliflozin as add- J Med Econ，2020，23（2）：193-203.
on to basal insulin[J]. Value Health，2017，20（9）：A474. [28] VILJOEN A，HOXER C S，JOHANSEN P，et al. Evalua‐
[19] STAFFORD S，BECH P G，FRIDHAMMAR A，et al. tion of the long-term cost-effectiveness of once-weekly
Cost-effectiveness of once-weekly semaglutide 1 mg ver‐ semaglutide versus dulaglutide for treatment of type 2 dia‐
sus canagliflozin 300 mg in patients with type 2 diabetes betes mellitus in the UK[J]. Diabetes Obes Metab，2019，
mellitus in a Canadian setting[J]. Appl Health Econ 21（3）：611-621.
Health Policy，2022，20（4）：543-555. [29] MALKIN S J P，RUSSEL-SZYMCZYK M，PSOTA M，et
[20] RUAN Z，UNG C O L，SHEN Y，et al. Long-term cost- al. The management of type 2 diabetes with once-weekly
effectiveness analysis of once-weekly semaglutide versus semaglutide versus dulaglutide： a long-term cost-
dulaglutide in patients with type 2 diabetes with in- effectiveness analysis in Slovakia[J]. Adv Ther，2019，36
adequate glycemic control in China[J]. Diabetes Ther， （8）：2034-2051.
2022，13（10）：1737-1753. [30] MALKIN S J P，RUSSEL-SZYMCZYK M，LIIDEMANN
[21] ZUPA M F，CODARIO R A，SMITH K J. Cost- G，et al. Once-weekly semaglutide versus once-daily lira‐
effectiveness of empagliflozin versus weekly semaglutide glutide for the treatment of type 2 diabetes：a long-term
as add-on therapy for type 2 diabetes[J]. J Comp Eff Res， cost-effectiveness analysis in Estonia[J]. Diabetes Ther，
2021，10（15）：1133-1141. 2019，10（1）：159-176.
[22] RUAN Z，YANG L S，SHI H H，et al. The cost- [31] HUNT B，MALKIN S J P，MOES R G J，et al. Once-
effectiveness of once-weekly semaglutide compared with weekly semaglutide for patients with type 2 diabetes：a
other GLP-1 receptor agonists in type 2 diabetes：a syste- cost-effectiveness analysis in the Netherlands[J]. BMJ
matic literature review[J]. Expert Rev Pharmacoecon Out‐ Open Diabetes Res Care，2019，7（1）：e000705.
comes Res，2021，21（2）：221-233. [32] GÆDE P，JOHANSEN P，TIKKANEN C K，et al. Correc‐
[23] MARTÍN V，VIDAL J，MALKIN S J P，et al. Evaluation tion to：management of patients with type 2 diabetes with
of the long-term cost-effectiveness of once-weekly sema‐ once-weekly semaglutide versus dulaglutide，exenatide
glutide versus dulaglutide and sitagliptin in the Spanish ER，liraglutide and lixisenatide：a cost-effectiveness analy‐
setting[J]. Adv Ther，2020，37（10）：4427-4445. sis in the Danish setting[J]. Diabetes Ther，2019，10（4）：
[24] JOHANSEN P，CHUBB B，HUNT B，et al. Evaluating 1319-1321.
the long-term cost-effectiveness of once-weekly semaglu‐ [33] ERICSSON Å，FRIDHAMMAR A. Cost-effectiveness of
tide versus once-daily liraglutide for the treatment of type once-weekly semaglutide versus dulaglutide and lixisena‐
2 diabetes in the UK[J]. Adv Ther，2020，37（5）：2427- tide in patients with type 2 diabetes with inadequate glyce‐
2441. mic control in Sweden[J]. J Med Econ，2019，22（10）：997-
[25] HALLÉN N，CARVALHO D，COSTA C，et al. PDB32 A 1005.
LONG-TERM cost-effectiveness analysis of treatments [34] KRISTENSEN S L，RØRTH R，JHUND P S，et al. Cardio‐
for type 2 diabetes in Portugal：once-weekly semaglutide vascular，mortality，and kidney outcomes with GLP-1 re‐
1 mg versus once-daily empagliflozin 25 mg[J]. Value ceptor agonists in patients with type 2 diabetes：a syste-
Health，2020，23：S511. matic review and meta-analysis of cardiovascular outcome
[26] HALLÉN N，DJEKIC D，IOANNIDIS I，et al. PDB36 trials[J]. Lancet Diabetes Endocrinol，2019，7（10）：
LONG-TERM cost-effectiveness analyses of once-weekly 776-785.
semaglutide 1 mg versus empagliflozin 25 mg for treat‐ （收稿日期：2022-12-27 修回日期：2023-05-30）
ment of type 2 diabetes in three countries：Bosnia and （编辑：陈 宏）

· 1508 · China Pharmacy 2023 Vol. 34 No. 12 中国药房 2023年第34卷第12期